Currently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs [6], which may benefit patients with high risk of atherosclerotic cardiovascular disease, such as diabetes mellitus. Here, PCSK9 is linked to diabetes mellitus.